2026/11/17
Mycenax Wins Bronze Award in Manufacturing Technology at the 2026 National Pharmaceutical Technology Research and Development Award for its AI-Powered Digital Twin Purification Platform

Highlights

  • Mycenax (TPEx: 4726) won the Bronze Award in the Manufacturing Technology category at the 2026 National Pharmaceutical Technology Research and Development Award, one of 13 winners selected from 41 applications
  • In partnership with Cytiva, Mycenax adopted GoSilico™ digital twin technology to build predictive models from a small set of key experiments, replacing extensive trial and error
  • Virtual simulation identifies optimal process conditions and accurately predicts yield, purity and process time, shortening development timelines and lowering costs
  • Focused on complex protein therapeutics such as bispecific and multispecific antibodies, Mycenax is moving beyond traditional contract manufacturing toward smart manufacturing and advanced process development

 


 

[Taipei, Taiwan – November 17, 2026]

 

Mycenax Biotech Inc. (TPEx: 4726) has won the Bronze Award in the Manufacturing Technology category at the 2026 National Pharmaceutical Technology Research and Development Award (NPRDA) for its "AI-Powered Digital Twin Platform for Optimizing Purification Processes of Complex Protein Therapeutics," receiving the award at a ceremony held on November 17 at the National Biotechnology Research Park in Taipei. The award recognizes Mycenax's progress in bringing AI into bioprocessing and advancing from traditional contract manufacturing toward smart manufacturing and advanced process capabilities.

 

In partnership with global life sciences leader Cytiva, Mycenax adopted GoSilico™ digital twin technology to build a data-driven platform for developing purification processes for next-generation protein therapeutics. The platform builds high-accuracy predictive models from a limited set of key experiments, moving away from development approaches that rely on extensive trial and error. Virtual simulation rapidly explores optimal process conditions and accurately predicts key metrics such as yield, purity and process time, shortening development timelines and lowering the cost of experiments and consumables. The platform is particularly well suited to complex protein therapeutics such as bispecific and multispecific antibodies. It improves the efficiency and predictability of process development and speeds the path of next-generation biologics from research to commercialization, demonstrating Mycenax's ability to upgrade its CDMO capabilities through digital innovation.

 

Co-organized by the Taiwan Food and Drug Administration (Ministry of Health and Welfare) and the Industrial Development Administration (Ministry of Economic Affairs), the NPRDA is now in its 25th year. This year, 13 of the 41 submitted applications were selected as winners.

 

"This award reflects our team's years of process development experience and continuous innovation," said Dr. Pei-Jiun Chen, CEO & President of Mycenax. "I want to thank our R&D team for their hard work and our partner Cytiva for their support. This recognition is not only an endorsement of our technical achievements, but also an important milestone in Mycenax's ongoing drive toward smart manufacturing."

 

 

Photo: The NPRDA award ceremony at the National Biotechnology Research Park on November 17

 

Photo: GoSilico™ software interface

 


 

About Mycenax

 

Mycenax positions its Bio-CDMO brand around the core philosophy of "Big D, Strong M": Leveraging innovative development capabilities (D) and well-scalable manufacturing capacity (M), the company provides a fully integrated, one-stop shop for the development and manufacturing of both traditional and emerging biologics. Mycenax’s core value lies in its regulatory-compliant and highly market-competitive biologics development technologies and cGMP manufacturing facilities, seamlessly fulfilling the mission of bridging the gap between R&D achievements and pharmaceutical commercialization. With Taiwan as its central development and manufacturing hub, Mycenax integrates upstream and downstream industry chains to deliver comprehensive contract development and manufacturing services (CDMO).

 

Mycenax was established in September 2001, and current capital is NT$2.07 billion.

Stock Code: Mycenax (4726)

Official Website: http://www.mycenax.com

 

Press Contact:

Liru Yeh

Tel: +886-2-2655-8951 Ext. 6102

Email: liru.yeh@mycenax.com

 

Highlights

  • Mycenax (TPEx: 4726) won the Bronze Award in the Manufacturing Technology category at the 2026 National Pharmaceutical Technology Research and Development Award, one of 13 winners selected from 41 applications
  • In partnership with Cytiva, Mycenax adopted GoSilico™ digital twin technology to build predictive models from a small set of key experiments, replacing extensive trial and error
  • Virtual simulation identifies optimal process conditions and accurately predicts yield, purity and process time, shortening development timelines and lowering costs
  • Focused on complex protein therapeutics such as bispecific and multispecific antibodies, Mycenax is moving beyond traditional contract manufacturing toward smart manufacturing and advanced process development

 


 

[Taipei, Taiwan – November 17, 2026]

 

Mycenax Biotech Inc. (TPEx: 4726) has won the Bronze Award in the Manufacturing Technology category at the 2026 National Pharmaceutical Technology Research and Development Award (NPRDA) for its "AI-Powered Digital Twin Platform for Optimizing Purification Processes of Complex Protein Therapeutics," receiving the award at a ceremony held on November 17 at the National Biotechnology Research Park in Taipei. The award recognizes Mycenax's progress in bringing AI into bioprocessing and advancing from traditional contract manufacturing toward smart manufacturing and advanced process capabilities.

 

In partnership with global life sciences leader Cytiva, Mycenax adopted GoSilico™ digital twin technology to build a data-driven platform for developing purification processes for next-generation protein therapeutics. The platform builds high-accuracy predictive models from a limited set of key experiments, moving away from development approaches that rely on extensive trial and error. Virtual simulation rapidly explores optimal process conditions and accurately predicts key metrics such as yield, purity and process time, shortening development timelines and lowering the cost of experiments and consumables. The platform is particularly well suited to complex protein therapeutics such as bispecific and multispecific antibodies. It improves the efficiency and predictability of process development and speeds the path of next-generation biologics from research to commercialization, demonstrating Mycenax's ability to upgrade its CDMO capabilities through digital innovation.

 

Co-organized by the Taiwan Food and Drug Administration (Ministry of Health and Welfare) and the Industrial Development Administration (Ministry of Economic Affairs), the NPRDA is now in its 25th year. This year, 13 of the 41 submitted applications were selected as winners.

 

"This award reflects our team's years of process development experience and continuous innovation," said Dr. Pei-Jiun Chen, CEO & President of Mycenax. "I want to thank our R&D team for their hard work and our partner Cytiva for their support. This recognition is not only an endorsement of our technical achievements, but also an important milestone in Mycenax's ongoing drive toward smart manufacturing."

 

 

Photo: The NPRDA award ceremony at the National Biotechnology Research Park on November 17

 

Photo: GoSilico™ software interface

 


 

About Mycenax

 

Mycenax positions its Bio-CDMO brand around the core philosophy of "Big D, Strong M": Leveraging innovative development capabilities (D) and well-scalable manufacturing capacity (M), the company provides a fully integrated, one-stop shop for the development and manufacturing of both traditional and emerging biologics. Mycenax’s core value lies in its regulatory-compliant and highly market-competitive biologics development technologies and cGMP manufacturing facilities, seamlessly fulfilling the mission of bridging the gap between R&D achievements and pharmaceutical commercialization. With Taiwan as its central development and manufacturing hub, Mycenax integrates upstream and downstream industry chains to deliver comprehensive contract development and manufacturing services (CDMO).

 

Mycenax was established in September 2001, and current capital is NT$2.07 billion.

Stock Code: Mycenax (4726)

Official Website: http://www.mycenax.com

 

Press Contact:

Liru Yeh

Tel: +886-2-2655-8951 Ext. 6102

Email: liru.yeh@mycenax.com

 

返回列表 BACK
GO TOP